Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa et al. · Science · 2017
Good bacteria help fight cancer Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium Akkermansia muciniphila . Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson et al. and Gopalakrishnan et al. studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer. Science , this issue p. 91 , p. 104 , p. 97 ; see also p. 32
Cited by 5,611 works. doi:10.1126/science.aan3706
Authors
- Bertrand Routy
- Emmanuelle Le Chatelier
- Lisa Derosa
- Connie P.M. Duong
- Maryam Tidjani Alou
- Romain Daillère
- Aurélie Fluckiger
- Meriem Messaoudene
- Conrad Rauber
- María Paula Roberti
- Marine Fidelle
- Caroline Flament
- Vichnou Poirier-Colame
- Paule Opolon
- Christophe Klein
- Kristina Iribarren
- Laura Mondragón
- Nicolas Jacquelot
- Bo Qu
- Gladys Ferrere
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Fast gapped-read alignment with Bowtie 2
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- Direct Analysis of Genes Encoding 16S rRNA from Complex Communities Reveals Many Novel Molecular Species within the Human Gut
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- Neoantigens in cancer immunotherapy